Product Description: Clazakizumab is a monoclonal antibody with high affinity and specificity for the IL-6 (interleukin-6) cytokine. Clazakizumab may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Clazakizumab can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection[1][2].
Applications: COVID-19-anti-virus
Formula: N/A
References: [1]Mease PJ, et al. The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis. Arthritis Rheumatol. 2016 Sep;68(9):2163-73./[2]Vaidya G, et al. Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report. Transplant Proc. 2020 Nov;52(9):2711-2714.
CAS Number: 1236278-28-6
Molecular Weight: N/A
Research Area: Infection; Inflammation/Immunology
Solubility: H2O
Target: Interleukin Related;SARS-CoV